A Patient with Suspect Chronic Myeloid Leukemia: A Case Report
Abstract
Chronic myeloid leukemia (CML) is a type of cancer that starts in the blood-forming cells of the bone marrow. In contrast to other types of leukemia, chronic myeloid leukemia (CML) progresses slowly. This report covers a 52-year-old male patient who came to the emergency room at Wangaya Regional Hospital with weakness, nausea, and pallor. His weight had drastically decreased over the last few months. The clinical condition of the patient was that both eyes appeared anemic, and the abdominal examination revealed hepatomegaly. Complete blood count examination results showed the following results: leukocytes 222.73x103/µl, hemoglobin 7.3 g/dL, platelets 679x103/µl, neutrophil 87.5%, neutrophil/lymphocyte ratio 16.66%. The results of peripheral blood smear analysis showed that hyperleukocytosis, with the maturation stage of myelocyte cells with a percentage of myeloblasts 6%, promyelocytes 7%, myelocytes 6%, metamyelocytes 8%, neutrophils 10%, neutrophil segments 60%, other cells 3%. These examination results suggest chronic myeloid leukemia. However, to confirm the diagnosis, the BCR-ABL fusion protein must be expressed, which can be used to identify the presence or absence of the Philadelphia chromosome in patients diagnosed with chronic myeloid leukemia (CML).
Keywords
Full Text:
PDFReferences
Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. Review Article European LeukemiaNet recommendations for the management of chronic myeloid leukemia : 2013. Blood. 2013;122(6):872–84.
O’Brien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E, et al. Chronic Myelogenous Leukemia, Version 1.2014. J Natl Compr Canc Netw. 2013 Nov;11(11):1327–40.
Bintoro UY. Leukemia Granulositik Kronik. Dalam Buku Ajar Ilmu Penyakit Dalam. Tjokropraw. Surabaya: Airlangga University Press; 2015.
Cilloni D, Saglio G. Molecular pathways: BCR-ABL. Clin cancer Res an Off J Am Assoc Cancer Res. 2012 Feb;18(4):930–7.
Cortes J, Kantarjian H. How I treat newly diagnosed chronic phase CML. Blood. 2012 Aug;120(7):1390–7.
Bintoro SUY. Chronic Myeloid Leukemia Perkembangan Baru dalam Tata Laksana dan Implikasi Terhadap Ketahanan Hidup. Surabaya: Airlangga University Press; 2019.
Gotlib J, Maxson JE, George TI, Tyner JW. The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment. Blood. 2013 Sep;122(10):1707–11.
Hehlmann R. How I treat CML blast crisis. Blood. 2012 Jul;120(4):737–47.
Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020 Jun;95(6):691–709.
Jabbour E. Chronic myeloid leukemia : 2020 update on diagnosis , therapy and monitoring. 2020;(March):691–709.
Ashariati A, Ugroseno S. Profile of BCR-ABL transcript levels based on Sokal prognostic score in chronic myeloid leukemia patients treated with imatinib. Acta Med Indones. 2013 Apr;45(2):107–13.
Kang ZJ, Liu YF, Xu LZ, Long ZJ, Huang D, Yang Y, et al. The Philadelphia chromosome in leukemogenesis. Chin J Cancer. 2016 May;35:48.
Arun AK, Senthamizhselvi A, Mani S, Vinodhini K, Janet NB, Lakshmi KM, et al. Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients. Int J Lab Hematol. 2017 Jun;39(3):235–42.
Diamantopoulos PT, Viniou NA. Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches. Front Oncol. 2021;11:722507.
Verma D, Kantarjian HM, Jones D, Luthra R, Borthakur G, Verstovsek S, et al. Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood. 2009 Sep;114(11):2232–5.
DOI: https://doi.org/10.24853/mmj.5.2.116-121
Refbacks
- There are currently no refbacks.
Indexed by:
Work is distributed under the Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright of Muhammadiyah Medical Journal (e issn: 2721-317X)